Novartis Trileptal Label Adds Warning On Dermatological Reactions
This article was originally published in The Pink Sheet Daily
Executive Summary
Warning highlights reports of Stevens-Johnson Syndrome and toxic epidermal necrolysis with use of the seizure therapy. The reactions may be life threatening, the warning says. Labeling also adds a precaution on multi-organ hypersensitivity reactions.
You may also be interested in...
FDA Warns Novartis, Shire On Misbranding
Shire pulls Fosrenol promos, calling them an “an unfortunate error.”
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.